[HTML][HTML] A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
Several editions of the World Health Organization (WHO) classifications of lympho-
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
MR Grever, O Abdel-Wahab… - Blood, The Journal …, 2017 - ashpublications.org
Hairy cell leukemia is an uncommon hematologic malignancy characterized by
pancytopenia and marked susceptibility to infection. Tremendous progress in the …
pancytopenia and marked susceptibility to infection. Tremendous progress in the …
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti… - Nature medicine, 2015 - nature.com
Colorectal cancers (CRCs) evolve by a reiterative process of genetic diversification and
clonal evolution. The molecular profile of CRC is routinely assessed in surgical or bioptic …
clonal evolution. The molecular profile of CRC is routinely assessed in surgical or bioptic …
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia
Genomic studies have revealed the complex clonal heterogeneity of chronic lymphocytic
leukemia (CLL). The acquisition and selection of genomic aberrations may be critical to …
leukemia (CLL). The acquisition and selection of genomic aberrations may be critical to …
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia
E Tiacci, JH Park, L De Carolis, SS Chung… - … England Journal of …, 2015 - Mass Medical Soc
Background BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed
the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell …
the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell …
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
TP53 mutations are strong predictors of poor survival and refractoriness in chronic
lymphocytic leukemia (CLL) and have direct implications for disease management. Clinical …
lymphocytic leukemia (CLL) and have direct implications for disease management. Clinical …
Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia
E Tiacci, L De Carolis, E Simonetti… - … England Journal of …, 2021 - Mass Medical Soc
Background Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF
V600E kinase–activating mutation plays a pathogenetic role. In clinical trials involving …
V600E kinase–activating mutation plays a pathogenetic role. In clinical trials involving …
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms
M Varettoni, L Arcaini, S Zibellini… - Blood, The Journal …, 2013 - ashpublications.org
A study has shown that MYD88 (L265P) is a recurring somatic mutation in Waldenström's
macroglobulinemia (WM). We developed an allele-specific polymerase chain reaction …
macroglobulinemia (WM). We developed an allele-specific polymerase chain reaction …
High prevalence of MAP2K1 mutations in variant and IGHV4-34–expressing hairy-cell leukemias
JJ Waterfall, E Arons, RL Walker, M Pineda, L Roth… - Nature …, 2014 - nature.com
To understand the genetic mechanisms driving variant and IGHV4-34–expressing hairy-cell
leukemias, we performed whole-exome sequencing of leukemia samples from ten affected …
leukemias, we performed whole-exome sequencing of leukemia samples from ten affected …
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development
D Rossi, V Trifonov, M Fangazio… - Journal of Experimental …, 2012 - rupress.org
Splenic marginal zone lymphoma (SMZL) is a B cell malignancy of unknown pathogenesis,
and thus an orphan of targeted therapies. By integrating whole-exome sequencing and copy …
and thus an orphan of targeted therapies. By integrating whole-exome sequencing and copy …